Printer Friendly

Potential use of bisphosphonates in invasive extramammary paget's disease: an immunohistochemical investigation.

1. Introduction

Extramammary Paget's disease (EMPD) is a skin adenocarcinoma that generally occurs in the anogenital region [1]. It usually affects older patients, and the lesions commonly develop in the vulva, penis, scrotum, perineum, perianal area, umbilicus, and axilla [1]. Invasive EMPD, although relatively rare, is reported to be highly metastatic to lymph nodes (47.1%) or even other organs (17.6%), including bone (5.9%) [2]. Histologically, both noninvasive EMPD and invasive EMPD show significant numbers of lymphocytes around the tumor mass.

The use of bisphosphonates (BPs) in malignancy, especially for osteolytic bone disease, has been increasing [3-5]. Recent reports suggested that BPs might have a direct antitumor effect beyond their beneficial effects on bone metastasis [3]. One of the possible explanations for the additional antitumor effects of BPs is that pharmacological inhibition of MMP9 by aminobisphosphonate decreases pro-MMP9 and VEGF in the serum and abrogates the suppressive function of immunosuppressive cells and induces the antitumor immune response both locally and at sites remote from the tumor [6].

In this study, we employed immunohistochemical staining for immunosuppressive macrophages and cytotoxic T cells in the lesional skin of patients with noninvasive EMPD and those with invasive EMPD.

2. Materials and Methods

2.1. Reagents. We used the following antibodies (Abs) for immunohistochemical staining: mouse monoclonal Abs for human CD8 (Dako A/S, Glostrup, Denmark), human granulysin (MBL LTD, Nagoya, Japan), anti-TIA1 Ab (Abcam, Cambridge, UK), antiperforin Ab (Kamiya Biomedical Company, Seattle, WA, USA), and human CD163 (Novocastra, UK), and rabbit polyclonal Abs for human MMP-9 (Abcam), human B7H1 (ProSci, Poway, CA, USA), and human arginase 1 (ARG1) (Life Span Bioscience, Seattle, WA).

2.2. Tissue Samples and Immunohistochemical Staining. We collected archival formalin-fixed paraffin-embedded skin specimens from 5 patients with noninvasive EMPD and 5 patients with invasive EMPD treated at the Department of Dermatology at Tohoku University Graduate School of Medicine. We summarized these cases in Table 1. We defined EMPD by the typical clinical features and histological characteristics such as Paget's cells, defined as rounded cells that are devoid of intracellular bridges and have large nuclei and ample cytoplasm, seen in the epidermis. Invasive EMPD is histologically defined as Paget's cells infiltrating in the dermis. Immunohistochemical staining for both invasive and noninvasive EMPD is cytokeratin 7+, cytokeratin 20-, PAS+, and Alcian blue stain (AB)+ in all cases. The 5 noninvasive EMPD samples and 5 invasive EMPD samples were processed for single staining of CD8, granulysin, TIA1, perforin, CD163, MMP9, B7H1, or ARG1 as described previously [7-9].

2.3. Assessment of Immunohistochemical Staining. Staining of infiltrated lymphocytes was examined in more than 5 random, representative fields from each section. The number of immunoreactive cells was counted using an ocular grid of 1 [cm.sup.2] at a magnification of 400x. Data are expressed as the mean [+ or -] standard deviation for Treg fractions in each skin disorder.

2.4. Statistical Analysis. For a single comparison of 2 groups, Student's 1-test was used. The level of significance was set at P = 0.05.

3. Results

3.1. CD8, Granulysin, TIA-1, and Perforin in Invasive and NonInvasive EMPD. First, to compare the profiles of tumor-infiltrating cytotoxic T lymphocytes between invasive and noninvasive EMPD, we employed immunohistochemical staining for CD8 (Figures 1(a) and 1(b)), granulysin (Figures 1(c) and 1(d)), TIA-1 (Figures 1(e) and 1(f)), and perforin (Figures 1(g) and 1(h)). The numbers of granulysin+ cells and [perforin.sup.+] cells were significantly lower in invasive EMPD than in noninvasive EMPD (granulysin: invasive EMPD versus noninvasive EMPD; 20.7 [+ or -] 8.1 versus 49.0 [+ or -] 15.9) (perforin: invasive EMPD versus noninvasive EMPD; 3.7 [+ or -] 1.2 versus 18.7 [+ or -] 4.0) (P < 0.05). In contrast, there was no significant difference in the numbers of CD8+ and TIA-1+ cells in the peritumoral areas of invasive and noninvasive EMPD (CD8: invasive EMPD versus noninvasive EMPD; 249 [+ or -] 54.4 versus 349 [+ or -] 64.3) (TIA-1: invasive EMPD versus noninvasive EMPD; 58.0 [+ or -] 11.4 versus 73.3 [+ or -] 19.1). We summarize the numbers of cytotoxic cells in Figure 2. As we previously described, the ratio of [Foxp3.sup.+] cells to CD3, CD4 and CD25 positive cells was significantly lower in invasive EMPD [7].

3.2. CD163, B7H1, MMP-9, and ARG1 in Invasive EMPD. To further investigate the profiles of immunosuppressive cells around the tumors in invasive and noninvasive EMPD, we performed immunohistochemical staining of CD163 (Figures 3(a) and 3(b)) as well as the functional markers for M2 macrophages, MMP-9 (Figures 3(c) and 3(d)), B7H1 (Figures 3(e) and 3(f)), and ARG1 (Figures 3(g) and 3(h)). Only in invasive EMPD were dense [CD163.sup.+] macrophages detected throughout the dermis. Interestingly, the expression of MMP-9, B7H1, and ARG1 was observed at the same areas as the [CD163.sup.+] macrophage-infiltrating areas of invasive EMPD (Figures 3(d), 3(f), and 3(h)), whereas few MMP-9, B7H1, and ARG1 expressing cells were detected in noninvasive EMPD (Figures 3(c), 3(e), and 3(g)). We summarized the number of [CD163.sup.+] cells in Figure 3(i). The numbers of [CD163.sup.+] cells were significantly higher in invasive EMPD than in noninvasive EMPD (Figure 3(i)) (CD163: invasive EMPD versus noninvasive EMPD; 3.0 [+ or -] 1.4 versus 89.2 [+ or -] 15.8) (P < 0.05).

4. Discussion

Immunosuppressive macrophages, M2 macrophages, and myeloid derived suppressor cells (MDSC), together with Tregs, were reported to promote an immunosuppressive environment in the tumor-bearing host [10-12]. Alternatively activated macrophages, M2 macrophages, have an important role in the response to parasite infection, tissue remodeling, angiogenesis, and tumor progression [13]. MDSCs are a heterogeneous population of cells that promote an immunosuppressive environment in tumor-bearing hosts [10]. In human, MDSCs are a less defined and phenotypically heterogeneous group of cells that have only immunosuppressive activities in common. Among them, arginase 1 (ARG1) is reported as a marker for polymorphonuclear MDSCs [10]. In this aspect, MDSCs in human are translated [CD163.sup.+] , [ARG1.sup.+], and alternatively activated, tumor-associated macrophages (TAM) [11].

MMP-9 is a stromal factor that regulates the mobilization of hematopoietic stem cells from the bone marrow niche by solubilizing the membrane-bound form of c-KitL [14]. Because it remodels the extracellular matrix and promotes the sprouting and growth of new blood vessels by making VEGF available to the VEGFR-2/flk receptor on endothelial cells, MMP-9 is a linchpin in tumor progression 14]. Actually, several reports revealed that the expression of MMP-9 on tumors was correlated with the progression or prognosis of several skin tumors such as malignant melanoma, squamous cell carcinoma, basal cell carcinoma, mycosis fungoides, extramammary Paget's disease, and angiosarcoma [7, 9, 141-9]. In addition, other reports described that the expression of MMP-9 on immunosuppressive macrophages in the tumor microenvironment contributed to tumor invasion and metastasis [6, 7, 9, 19, 20]. In aggregate, these reports suggest that increased numbers of [MMP-9.sup.+] cells around the tumor might be connected with [CD163.sup.+] M2 macrophages and contribute to the poor prognosis of the tumor-bearing host.

The use of bisphosphonates (BPs) in malignancy, especially osteolytic bone disease, has been increasing [3-5]. Recent reports suggested that BPs might have a direct antitumoral effect beyond their beneficial effect on bone metastasis [3]. Various investigations have demonstrated the synergistic, antiproliferation effect of BPs with conventional chemotherapeutic drugs in vitro (Figure 4) [4, 5]. Indeed, Fehm et al. reported that the antitumor effect of BPs for breast cancer cells in vitro is equal or even superior to those of chemotherapeutic drugs, such as DTX [5]. In addition, from the immunological point of view, it was reported that pharmacological inhibition of MMP9 by aminobisphosphonate decreased pro-MMP9 and VEGF in the serum and abrogated the induction of MDSC in the tumor microenvironment [6]. In aggregate, the administration of BPs in tumor-bearing hosts might abrogate the suppressive function of immunosuppressive cells, such as MDSC and M2 macrophages, and induce the antitumor immune response at the local site of the tumor. Indeed, in this report, we employed immunohistochemical staining for invasive and noninvasive EMPD and revealed that both invasive and noninvasive EMPD contains substantial numbers of cytotoxic T cells (CD8, granulysin, TIA1, and perforin). Interestingly, only invasive EMPD possessed substantial numbers of [CD163.sup.+] M2 macrophages and [MMP-9.sup.+] cells, [B7H1.sup.+] cells, and [ARG1.sup.+] cells around the tumor, whereas few [CD163.sup.+] M2 macrophages, [MMP-9.sup.+] cells, [B7H1.sup.+] cells, and [ARG1.sup.+] cells were observed in noninvasive EMPD.

5. Conclusion

Our data suggest that the administration of BPs for patients with invasive EMPD by targeting the immunosuppressive macrophages might be effective not only for the prevention of bone metastasis, but also for the prevention of the progression of the disease both locally and at sites remote from the tumor. Since we did not directly assess the suppressive function of these infiltrating M2 macrophages or cytotoxic T cells, further analysis of the mechanisms underlying this phenomenon will be necessarily to confirm our limited observation. 10.1155/2013/164982

Conflict of Interests

The authors declare that there is no conflict of interests.


[1] J. Lloyd and A. M. Flanagan, "Mammary and extramammary Paget's disease," Journal of Clinical Pathology, vol. 53, no. 10, pp. 742-749, 2000.

[2] T. Shiomi, T. Noguchi, H. Nakayama et al., "Clinicopathological study of invasive extramammary Paget's disease: subgroup comparison according to invasion depth," Journal of the European Academy of Dermatology and Venereology, 2012.

[3] D. Heymann, B. Ory, F. Gouin, J. R. Green, and F. Redini, "Bisphosphonates: new therapeutic agents for the treatment of bone tumors," Trends in Molecular Medicine, vol. 10, no. 7, pp. 337-343, 2004.

[4] S. P. Jagdev, R. E. Coleman, C. M. Shipman, A. Rostami-H. A., and P. I. Croucher, "The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel," British Journal of Cancer, vol. 84, no. 8, pp. 1126-1134, 2001.

[5] T. Fehm, M. Zwirner, D. Wallwiener, H. Seeger, and H. Neubauer, "Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay," BMC Cancer, vol. 12, article 308, 2012.

[6] C. Melani, S. Sangaletti, F. M. Barazzetta, Z. Werb, and M. P. Colombo, "Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma," Cancer Research, vol. 67, no. 23, pp. 11438-11446, 2007.

[7] T. Fujimura, Y. Kambayashi, T. Hidaka, A. Hashimoto, T. Haga, and S. Aiba, "Comparison of [Foxp3.sup.+] regulatory T-cells and [CD163.sup.+] macrophages in invasive and non-invasive extramammary Paget's disease," Acta Dermato-Venereologica, vol. 92, pp. 625-628, 2012.

[8] J. Gadiot, A. I. Hooijkaas, A. D. M. Kaiser, H. Van Tinteren, H. Van Boven, and C. Blank, "Overall survival and PD-L1 expression in metastasized malignant melanoma," Cancer, vol. 117, no. 10, pp. 2192-2201, 2011.

[9] Y. Kambayashi, T. Fujimura, and S. Aiba, "Comparison of immunosuppressive cells and immunomodulatory cells in kerartoacanthoma and invasive squamous cell carcinoma," Acta Dermato-Venereologica. In press.

[10] T. Fujimura, K. Mahnke, and A. H. Enk, "Myeloid derived suppressor cells and their role in tolerance inuction in cancer," Journal of Dermatological Science, vol. 59, pp. 1-6, 2010.

[11] M. M. Tiemessen, A. L. Jagger, H. G. Evans, M. J. C. Van Herwijnen, S. John, and L. S. Taams, "[CD4.sup.+][CD25.sup.+][Foxp3.sup.+] regulatory T cells induce alternative activation of human monocytes/macrophages," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19446-19451, 2007.

[12] T. Fujimura, S. Ring, V. Umansky, K. Mahnke, and A. H. Enk, "Regulatory T cells (Treg) stimulate B7-H1 expression in myeloid derived suppressor cells (MDSC) in ret melanomas," Journal of Investigative Dermatology, vol. 132, pp. 1239-1246, 2012.

[13] T. Satoh, O. Takeuchi, A. Vandenbon et al., "The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection," Nature Immunology, vol. 11, no. 10, pp. 936-944, 2010.

[14] B. Heissig, K. Hattori, S. Dias et al., "Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand," Cell, vol. 109, no. 5, pp. 625-637, 2002.

[15] P. P. Vihinen, M. Hernberg, M. S. Vuoristo et al., "A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-[alpha]2a as first line treatment in metastatic melanoma," Melanoma Research, vol. 20, no. 4, pp. 318-325, 2010.

[16] G. Zhang, X. Luo, E. Sumithran et al., "Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression," Oncogene, vol. 25, no. 55, pp. 7260-7266, 2006.

[17] N. Monhian, B. S. Jewett, S. R. Baker, and J. Varani, "Matrix metalloproteinase expression in normal skin associated with basal cell carcinoma and in distal skin from the same patients," Archives of Facial Plastic Surgery, vol. 7, no. 4, pp. 238-243, 2005.

[18] H. Rasheed, M. M. Tolba Fawzi, M. R. E. Abdel-Halim, A. M. Eissa, N. Mohammed Salem, and S. Mahfouz, "Immunohistochemical study of the expression of matrix metalloproteinase-9 in skin lesions of mycosis fungoides," American Journal of Dermatopathology, vol. 32, no. 2, pp. 162-169, 2010.

[19] M. Ishibashi, T. Fujimura, A. Hashimoto et al., "Successful treatment of MMP9-expressing angiosarcoma with low-dose docetaxel and biphosphonate," Case Reports in Dermatology, vol. 4, no. 1, pp. 5-9, 2012.

[20] J. S. Pettersen, J. Fuentes-Duculan, M. Suarez-Farinas et al., "Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated," Journal of Investigative Dermatology, vol. 131, pp. 1322-1330, 2011.

Taku Fujimura, Sadanori Furudate, Yumi Kambayashi, and Setsuya Aiba

Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan

Correspondence should be addressed to Taku Fujimura;

Received 1 February 2013; Accepted 14 March 2013

Academic Editor: Giacomina Brunetti

TABLE 1: Summary for 10 cases of invasive or noninvasive EMPD.
We summarized the treatment, clinical stage, and prognosis
of invasive or noninvasive EMPD.

              Ages/sex     Radical therapy

Noninvasive EMPD
  Case 1        82/M     Surgical resection
  Case 2        70/M     Surgical resection
  Case 3        92/M     Surgical resection/
                           radiation (60G)
  Case 4        81/M     Surgical resection
  Case 5        70/M     Surgical resection

Invasive EMPD
  Case 6        69/M     Surgical resection/
                           radiation (60G)
  Case 7        78/M     Surgical resection/
  Case 8        78/F     Surgical resection
  Case 9        80/M     Surgical resection
  Case 10       82/M     Surgical resection/

                Stage         Prognosis

Noninvasive EMPD
  Case 1       Stage I    Complete remission
  Case 2       Stage I    Complete remission
  Case 3       Stage I    Complete remission
  Case 4       Stage I    Complete remission
  Case 5       Stage I    Complete remission

Invasive EMPD
  Case 6      Stage IV    Dead by multiple
  Case 7      Stage III   Complete remission
  Case 8      Stage II    Complete remission
  Case 9      Stage II    Complete remission
  Case 10     Stage III   Complete remission
COPYRIGHT 2013 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Fujimura, Taku; Furudate, Sadanori; Kambayashi, Yumi; Aiba, Setsuya
Publication:Journal of Immunology Research
Date:Jan 1, 2013
Previous Article:Modulatory effect of 1,25-dihydroxyvitamin [D.sub.3] on IL1[beta]-Induced RANKL, OPG, TNF[alpha], and IL-6 expression in human rheumatoid synoviocyte...
Next Article:Immunological reaction in TNF-[alpha]-mediated osteoclast formation and bone resorption in vitro and in vivo.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |